

AP  
JFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Fred S. Lamb et al.  
Serial No. : 09/930,105  
Filed : August 15, 2001  
Title : USE OF CLC3 CHLORIDE CHANNEL BLOCKERS TO MODULATE  
VASCULAR TONE

Art Unit : 1617  
Examiner : Jennifer M. Kim

**Mail Stop Appeal Brief - Patents**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**BRIEF ON APPEAL**

The Final Office Action for this application was mailed August 24, 2004, and a Notice of Appeal was filed February 18, 2005.

**(1) Real Party in Interest**

The real party in interest is the University of Iowa Research Foundation.

**(2) Related Appeals and Interferences**

None.

**(3) Status of Claims**

Claims 1-21, 25-26, and 36-37 were canceled in the Reply to Office Action mailed November 2, 2004. Claim 30 was previously canceled.

Claims 22-24, 27-29, 31-35, and 38-43 are pending and stand finally rejected.

04/19/2005 TBESHAH1 00000006 09930105

01 FC:2402

250.00 DP

**CERTIFICATE OF MAILING BY FIRST CLASS MAIL**

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 15, 2005

Date of Deposit

Signature

*Caryl Harriman*

Caryl Harriman

Typed or Printed Name of Person Signing Certificate

**(4) Status of Amendments**

All amendments have been entered or, as indicated by the Examiner in the Advisory Action mailed November 26, 2004, will be entered for purposes of Appeal.

**(5) Summary of Claimed Subject Matter**

The claimed subject matter relates to methods for modulating vascular tone in a patient having compromised vascular tissue associated with erectile dysfunction, as well as methods for modulating penile vascular tone in a mammal in need thereof. The methods include administering a pharmaceutically effective amount of a chloride channel blocking agent or a pharmaceutically acceptable salt thereof. The claimed subject matter also relates to a method for treating erectile dysfunction, wherein the method includes administering a composition containing a CLC3 channel blocking agent or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

**(6) Grounds of Rejection**

(1) That the claims are anticipated by the Delaney *et al.* reference (Delaney and Langlands (1996) *The Breast* 5:53-54) as evidenced by U.S. Patent No. 5, 658,936 (the Kifor *et al.* patent). The Examiner stated that the Delaney *et al.* reference clearly teaches that a patient treated with tamoxifen exhibited significantly enhanced libido. The Examiner also stated that the Kifor *et al.* patent provides evidence of the equivalence between improvement in erectile function and increased libido. The Examiner further stated that Applicants' recitation in the claims of a mechanism for modulating penile vascular tone does not represent a patentable limitation, and that tamoxifen has been previously used to obtain the same pharmacological effect (enhanced erection) that would result from the claimed method.

(2) That the claims are unpatentable over the Delaney *et al.* reference as applied to claims 22-24, 27-29, 33-35, and 39-43, and further in view of U.S. Patent No. 6,266,560 (the Zhang *et al.* patent) and Drug Facts and Comparisons (1997). The Examiner stated that while the Delaney *et al.* reference does not expressly teach the route of administration set forth in claims 32 and 38, or the further administration of the agents set forth in claim 31, Drug Facts and Comparisons teaches that tamoxifen is commercially available in oral form, while the Zhang *et al.* patent

reports that vasodilators are useful for treatment of erectile dysfunction. Thus, the Examiner concluded that it would have been obvious to a person having ordinary skill in the art to administer tamoxifen orally. The Examiner also concluded that it would have been obvious to incorporate a vasodilator agent with tamoxifen because vasodilators are useful for treatment of erectile dysfunction.

(7) **Argument**

**Rejection #1: That the claims are anticipated by the Delaney *et al.* reference (Delaney and Langlands (1996) *The Breast* 5:53-54) as evidenced by U.S. Patent No. 5,658,936 (the Kifor *et al.* reference).**

Claims 22-24, 27-29, and 31-32 relate to methods for using a chloride channel blocking agent to modulate vascular tone in a patient having compromised vascular tissue associated with erectile dysfunction. Claims 33-42 relate to methods for using a chloride channel blocking agent to modulate penile vascular tone in a mammal in need thereof. Claim 43 recites a method for treating erectile dysfunction. Applicants respectfully assert that the rejection of the present claims as being anticipated by the Delaney *et al.* reference is incorrect.

First, the Delaney *et al.* reference fails to anticipate the present claims. The Delaney *et al.* reference discloses that one male patient on a tamoxifen regimen had experienced increased libido during his course of treatment. At no point does the Delaney *et al.* reference disclose that the patient had compromised vascular tissue associated with erectile dysfunction, as recited in claims 22-24, 27-29, and 31-32. Further, at no point does the Delaney *et al.* reference disclose that the patient was in need of modulated penile vascular tone as recited in claims 33-35 and 38-42, or was diagnosed with erectile dysfunction as recited in claim 43. While the Delaney *et al.* reference suggests that tamoxifen may have been the cause of the patient's increased libido, this reference fails to even suggest that tamoxifen might be useful to modulate penile vascular tone in a patient with erectile dysfunction.

Second, the Delaney *et al.* reference fails to establish a causative link between tamoxifen treatment and increased libido. The reference discloses that one male cancer patient experienced increased libido during a course of treatment with tamoxifen. According to the Delaney *et al.* reference, the patient began tamoxifen treatment in April 1993. Ten months later, in February

1994, he reported that he had experienced significantly enhanced libido for the immediately preceding 6 months. As such, the onset of increased libido did not occur until the patient had been taking tamoxifen for about four months. Moreover, when the patient was reevaluated in January 1995, his libido had returned to normal levels despite the fact that he continued tamoxifen treatment. Thus, the perceived side effect of increased libido was not observed until the patient had been on tamoxifen for a relatively long time, and it resolved before the patient discontinued his tamoxifen treatment.

The Delaney *et al.* reference does not report that any studies were conducted to determine whether the tamoxifen treatment was definitively linked to the patient's increase in libido. In addition, Delaney *et al.* did not attempt to establish whether the increased libido might have been linked to any of the other treatments to which the cancer patient had been subjected, including chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, as well as radiotherapy. In fact, the authors of the Delaney *et al.* reference were unsure as to the cause of the increased libido, as they speculate that it may have been related to the relatively young age of the patient. They do not disclose any evidence that tamoxifen treatment and increased libido were causatively linked.

In addition, the Delaney *et al.* reference discloses that the increase in libido observed in this one patient was contrary to other case reports in which tamoxifen therapy was associated with impotence. In fact, the Delaney *et al.* reference discloses that previous studies had found that 5 to 30 percent of men receiving tamoxifen experienced reduced libido. Thus, the Delaney *et al.* reference clearly teaches that the patient in question was an outlier, and that tamoxifen treatment would be expected to reduce libido rather than to increase libido.

Third, libido and erectile dysfunction are significantly different conditions; an improvement in erectile function cannot be equated with an increase in libido. Libido is a psychological phenomenon that is defined by the Merriam-Webster online dictionary as “<sup>1</sup>emotional or psychic energy that in psychoanalytic theory is derived from primitive biological urges and that is usually goal-directed; or <sup>2</sup>sexual drive.” Erectile dysfunction is a physiological condition that is defined by the On-Line Medical Dictionary as “a consistent inability to sustain an erection sufficient for sexual intercourse.” Copies of these definitions were submitted with Applicants' response dated November 2, 2004. Given these differences, increasing libido and

modulating penile vascular tone to treat erectile dysfunction are likely accomplished by different mechanisms. Thus, even if tamoxifen treatment was casually linked to increased libido, there would have been no reason to believe that it could be used to modulate penile vascular tone or to treat erectile dysfunction.

The Kifor *et al.* patent is consistent with the above definitions when it states that improved erectile function can include “any enhancement of the ability of a subject to maintain an erection, induce or improve ejaculation, induce or improve orgasm, and increase libido.” (See, column 7, lines 4-8 of the Kifor *et al.* patent.) Thus, an increase in libido may improve erectile dysfunction, but does not necessarily do so. As such, improved erectile function and increased libido are distinct and cannot be equated.

In summary, given the differences between libido and erectile dysfunction, together with the lack of evidence establishing that tamoxifen treatment was causally associated with one individual's increased libido, as well as the failure of the Delaney *et al.* reference to disclose that tamoxifen would be useful in a patient having compromised vascular tissue and/or erectile dysfunction, it is clear that the cited reference does not anticipate the present claims.

In light of the above, Applicants respectfully request withdrawal of the rejection of claims 22-24, 27-29, 33-35, and 39-43 under 35 U.S.C. § 102(b).

**Rejection #2: That the claims are unpatentable over the Delaney *et al.* reference as applied to claims 22-24, 27-29, 33-35, and 39-43, and further in view of U.S. Patent No. 6,266,560 (the Zhang *et al.* patent) and Drug Facts and Comparisons (1997).**

Claims 31 and 32 depend from claim 22, and claim 38 depends from claim 33. Thus, these claims relate to methods for using a chloride channel blocking agent to modulate vascular tone in a patient having compromised vascular tissue associated with erectile dysfunction, or to modulate penile vascular tone in a mammal in need thereof. As discussed above, the Delaney *et al.* reference discloses only that one male patient experienced increased libido during a portion of the time for which he was on a tamoxifen regimen. The patient was disclosed to be a 35 year-old breast cancer patient. At no point was he disclosed to have erectile dysfunction or to be in need of modulated penile vascular tone. Thus, the Delaney *et al.* reference fails to provide any

suggestion that tamoxifen might be useful to modulate vascular tone in a patient having compromised vascular tissue.

Moreover, the Delaney *et al.* reference teaches away from using tamoxifen to increase libido. In fact, Delaney *et al.* teach that tamoxifen treatment is more likely to result in reduced libido than increased libido. In addition, libido and erectile function are very different conditions, as described above. Even if libido and erectile dysfunction could be equated, which they cannot, a subject having erectile dysfunction or compromised penile vascular tissue surely would not have been motivated by the Delaney *et al.* reference to use tamoxifen to treat his condition. This is particularly true given the four-month lag time between administration of tamoxifen and the reported onset of increased libido, as well as the reduction in libido to normal levels prior to discontinuation of tamoxifen therapy. As such, a person of ordinary skill in the art reading the Delaney *et al.* reference would not have been motivated to use a chloride channel blocking agent such as tamoxifen to modulate vascular tone in a patient, or to modulate penile vascular tone in a mammal in need thereof.

The Zhang *et al.* patent and the Drug Facts and Comparisons reference fail to remedy the deficiencies of the Delaney *et al.* reference. At no point do either of these references suggest that a chloride channel blocking agent such as tamoxifen would be useful either to modulate vascular tone in a patient having compromised vascular tissue associated with erectile dysfunction or to modulate penile vascular tone in a mammal in need thereof. Moreover, at no point does the combination of the Delaney *et al.* reference with the Zhang *et al.* patent and the Drug Facts and Comparisons reference suggest that a chloride channel blocker would be useful to modulate vascular tone either alone or in combination with another agent (*e.g.*, a vasodilator), regardless of how it was administered. Thus, the combination of these three references fails to render claims 31, 32, and 38 obvious.

In light of the above, Applicants respectfully request withdrawal of the rejection of claims 31, 32, and 38 under 35 U.S.C. § 103(a).

Applicant : Fred S. Lamb et al.  
Serial No. : 09/930,105  
Filed : August 15, 2001  
Page : 7 of 10

Attorney's Docket No.: 17023-017001 / N9-19

The brief fee of \$250 is enclosed. Please apply any other charges or credits to Deposit  
Account No. 06-1050.

Respectfully submitted,

Date: April 15, 2005

Elizabeth N. Kaytor  
Elizabeth N. Kaytor, Ph.D.  
Reg. No. 53,103


Fish & Richardson P.C., P.A.  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696

60285895.doc

### Appendix of Claims

22. A method to modulate vascular tone in a patient having compromised vascular tissue, comprising administering a pharmaceutically effective amount of a chloride channel blocking agent, or a pharmaceutically acceptable salt thereof, wherein the compromised vascular tissue is associated with erectile dysfunction.

23. A method of claim 22, wherein the chloride channel blocking agent is a compound of Formula I



I

wherein either  $R^4$  is H or a lower alkyl radical and  $R^5$  is a lower alkyl radical, or  $R^4$  and  $R^5$  are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

$R^6$  is H or a lower alkyl radical;

$R^7$  is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

$R^8$  is H or OH; and

n is 2;


or a pharmaceutically acceptable salt thereof.

24. A method of claim 23, wherein the compound is 1-p- $\beta$ -dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.

27. A method of claim 22, wherein the chloride channel is a CLC3 channel.



28. The method of claim 27, wherein blocking the CLC3 channel results in diminished vasoconstriction to norepinephrine.
29. The method of claim 22, wherein the agent modulates vascular tone by enhancing vasodilation.
31. A method of claim 22, further comprising administering a pharmaceutically effective compound selected from an anti-diabetes agent, an anti-hypertension agent, an anti-coronary artery disease agent, an anti-restenosis agent, and a vasodilatory agent.
32. A method of claim 22, wherein the agent is administered intravenously or orally.
33. A method to modulate penile vascular tone in a mammal in need thereof, said method comprising administering a pharmaceutically effective amount of a chloride channel blocking agent, or a pharmaceutically acceptable salt thereof.
34. A method of claim 33, wherein the chloride channel blocking agent is a compound of Formula I



wherein either  $R^4$  is H or a lower alkyl radical and  $R^5$  is a lower alkyl radical, or  $R^4$  and  $R^5$  are joined together with the adjacent nitrogen atom to form a heterocyclic radical;

$R^6$  is H or a lower alkyl radical;

$R^7$  is H, halo, OH, a lower alkyl radical, or is a buta-1,3-dienyl radical which together with the adjacent benzene ring forms a naphthyl radical;

$R^8$  is H or OH; and

n is 2;

or a pharmaceutically acceptable salt thereof.

35. A method of claim 34, wherein the compound administered is 1-p- $\beta$ -dimethylaminoethoxyphenyl-trans-1, 2-diphenylbut-1-ene, or a pharmaceutically acceptable salt thereof.
38. The method of claim 33, wherein the agent is administered orally or intravenously.
39. A method of claim 33, wherein the chloride channel is a CLC3 channel.
40. The method of claim 39, wherein blocking the CLC3 channel results in diminished vasoconstriction to norepinephrine.
41. The method of claim 39, wherein blocking the CLC3 channel reduces penile sympathetic tone.
42. The method of claim 41, wherein the reduction of penile sympathetic tone induces an erection.
43. A method for treating erectile dysfunction comprising administering a composition comprising a CLC3 channel blocking agent or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.